ONCOLYTICS BIOTECH INC. Adjustments For Depreciation And Amortisation Expense
ONCOLYTICS BIOTECH INC. (ONCY) reported Adjustments For Depreciation And Amortisation Expense of CAD 120.00 thousand for the 12-month period ending 2024-12-31, per its 20-F filed 2025-03-07.
Financial Statements › Expense Statement › Operating Expenses
ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense · last filed 2025-03-07
| Period end | Adjustments For Depreciation And Amortisation Expense 12 month | Adjustments For Depreciation And Amortisation Expense 12 month as first filed |
|---|---|---|
| 2024-12-31 | 120.00K CAD 20-F · filed 2025-03-07 | |
| 2023-12-31 | 81.00K CAD 20-F · filed 2025-03-07 | |
| 2022-12-31 | 93.00K CAD 20-F · filed 2025-03-07 | |
| 2021-12-31 | 130.00K CAD 20-F · filed 2024-03-12 | 130.24K CAD 20-F · filed 2022-03-03 |
| 2020-12-31 | 89.00K CAD 20-F · filed 2023-03-03 | 88.96K CAD 20-F · filed 2021-03-05 |
| 2019-12-31 | 122.98K CAD 20-F · filed 2022-03-03 | |
| 2018-12-31 | 95.38K CAD 20-F · filed 2021-03-05 | |
| 2017-12-31 | 90.77K CAD 20-F · filed 2020-03-06 | |
| 2016-12-31 | 162.23K CAD 20-F · filed 2019-03-15 | |
| 2015-12-31 | 180.41K CAD 20-F · filed 2018-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |